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SUMO-triggered ubiquitination of NR4A1 controls
macrophage cell death
Long Zhang*,1,4,, Feng Xie2,4,, Juan Zhang3, Peter ten Dijke3 and Fangfang Zhou*,2
Nuclear receptor NR4A1 has been implicated as a key regulator in a wide range of pathophysiological responses. As an immediate
early response gene, NR4A1 can be rapidly and potently induced by a variety of stimuli. Its induction is followed by its rapid
degradation, but the mechanism by which NR4A1 is degraded remains poorly understood. Here we show that nuclear receptor
NR4A1 is sumoylated by SUMO2/3. Upon poly-SUMO modification, NR4A1 can be targeted by the SUMO-dependent E3 ubiquitin
ligase RNF4 for polyubiquitination and subsequent degradation. The SUMO E3 ligase PIAS3 promotes SUMOylation and
polyubiquitination of NR4A1, while the SUMO protease SENP1 acts to de-conjugate SUMO. We demonstrate that this pathway is
important for rapid degradation of NR4A1 after induced by stress. Moreover, we identify two SUMO modification sites in NR4A1
that are critical for maintaining low levels of NR4A1 expression. Mutation of these two NR4A1 SUMO modification sites enhances
the stability of NR4A1. Importantly, we show that SUMOylation is critical in controlling NR4A1 function in inflammatory cytokine
signaling and controlling macrophage cell death. SUMOylation and subsequent ubiquitination on NR4A1 mitigates its inhibition of
innate immune signaling, such as TNF-α- and IL-1β-induced NF-κB activation. This mechanism of sequential SUMOylation and
ubiquitination, which together control the degradation of NR4A1, could be exploited for the therapeutic treatment of diseases with
NR4A1 involvement.
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SUMOmodification, which involves the covalent attachment of
SUMO to a diverse array of proteins, regulates a wide range of
cellular processes, including transcription, replication, chro-
mosome segregation, and DNA repair. SUMO, which stands
for small ubiquitin-related modifier, becomes conjugated to its
substrates via the heterodimeric SUMOE1 activating enzyme,
a single SUMO E2 (UBE2I) conjugating enzyme, and a
restricted set of E3 protein ligases that include ‘protein inhibitor
of activated STAT’ (PIAS) family members.1,2 Although the E1
and E2 enzymes alone can modify most substrates in vitro, an
E3 ligase is usually required for selective and effective
recognition of substrates in vivo.3–5 SUMO-specific proteases
(SENPs) can cleave SUMO from target proteins, making
SUMOylation a reversible and dynamic process.6 In most
cases, SUMO modification occurs within a consensus
modification site (ψKxD/E, where ψ represents a bulky
hydrophobic group).7 Similar to ubiquitin, SUMO can be
covalently linked and thus form chains (polySUMO) via
internal lysine SUMOylation sites.8,9
Four SUMO isoforms, termed SUMO1-4, have been
identified in vertebrates. SUMO1, -2, and -3 are conjugated
to distinct substrates in vivo, and SUMO2 and -3 are very
similar in terms of structure and function. At present, it remains
unclear whether SUMO4 is conjugated to cellular proteins.
SUMO2 and -3 have a lysine at position 11 in a consensus
sequence.10 SUMO1 lacks such a site and does not contribute
efficiently to SUMO chains. Proteins that are SUMOylated can
associate in a non-covalent manner with other proteins via
their SUMO interaction motifs (SIMs). Unlike lysine
48-mediated ubiquitination, SUMOylation does not directly
target its substrates to proteosomal degradation. However,
recent studies demonstrated that poly-SUMO-modified
proteins can trigger degradation through the ubiquitin-media-
ted proteasome pathway and indirectly through SUMO-
targeted SIM (SUMO-interacting motif) domain-containing
ubiquitin ligases, such as the RING finger protein RNF4 and
RNF111, which contains several SIMs.8,11–16
Nuclear receptor 4A (NR4A1), which is also called Nur77,
TR3, and NGF-IB, is a member of the steroid nuclear hormone
receptor superfamily. It is part of the NR4A group, which
includes NR4A2 and NR4A3. In contrast to classic steroid
receptors that require ligand activation, NR4A family members
are constitutively active.17,18 NR4A plays a critical role in a
large spectrum of pathophysiological processes.19–22 Speci-
fically, NR4A is an immediate early response gene that can be
induced in different cell types and tissues by growth factors,
stimuli, and stress.23–25 NR4A1 and NR4A3 are required for
T-cell receptor-mediated apoptosis.26 Although NR4A1 and
NR4A3 single-knockout mice do not exhibit any thymic or
peripheral T-cell death, NR4A1 and NR4A3 double-knockout
mice develop acutemyeloid leukemia, revealing the redundant
functions of these family members.27 Reduced NR4A gene
dosage leads to mixed myelodysplastic/myeloproliferative
neoplasms in mice.28 NR4A1 is also involved in the regulation
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of apoptosis and cell death in several cell types.29,30
Specifically, apoptotic stimuli cause the translocation of
NR4A1 from the nucleus to themitochondria, which is followed
by the induction of cytochrome c release.31,32 In addition,
NR4A1 prevents atherogenesis and regulates hepatic glucose
metabolism in a mouse model.33–35
Because NR4A1 has multiple functions, its stability and
activity is likely to be carefully regulated. Several studies have
shown that NR4A1 transcriptional activity and stability can be
regulated by a series of coactivators SRC-2, PCAF, p300,
DRIP250, TRAP220 and Pin1, as well as by the corepressors
SHP and CRIF1 (refs 31,32,36–38). The post-translational
modifications, like phosphorylation and acetylation have also
been demonstrated to be important for the activity and function
of NR4As.37,39–41 Stimuli such as epidermal growth factor,
nerve growth factor, and phorbol myristate acetate can induce
NR4A1 phosphorylation,42,43 and this phosphorylation is
mediated by kinases such as Akt, pp90RSK, and Chk2
(refs 39,40,44).
Notably, the mechanism by which NR4A1 is rapidly
degraded after induction is not well understood. Here we
show that the nuclear receptor NR4A1 undergoes SUMO-
triggered ubiquitin-mediated degradation that is dependent on
the SUMO-targeted ubiquitin ligase RNF4. Further, we show
that SUMOylation is critical in controlling NR4A1 protein
stability and function in inflammatory cytokine signaling.
Results
NR4A1 undergoes SUMO modification. To investigate the
regulation of NR4A1, we examined its possible post-
translational modification by SUMO1, -2 and -3 in
HEK293T cells transfected with NR4A1 and SUMO1-3. As
shown in Figure 1a, ectopically expressed NR4A1 underwent
SUMO2/3 SUMOylation at a very low level. Strikingly, after
treatment with a proteasome inhibitor, NR4A1-SUMO2/3
conjugation increased dramatically. NR4A1-SUMO1 was
not detectable (Figure 1a). Importantly, analysis of
non-transfected cells demonstrated that NR4A1 was also
conjugated by SUMO2/3 in non-transfected cells (Figure 1b).
Taken together, these data indicate that NR4A1 undergoes
SUMO2/3 but not SUMO1-mediated SUMOylation and that
this post-translational modification by SUMO is coupled to
proteasome-mediated degradation of NR4A1.
NR4A1 interacts with the SUMO E3 ligase PIAS3. PIAS is
specific SUMO E3 ligase. When we performed a
co-immunoprecipitation in HEK293T cells transfected with
NR4A1 and a panel of SUMO E3 ligases, the PIAS3 ligase
showed the strongest interaction with NR4A1, while PIAS1
and PIASXα interacted only weakly with NR4A1 (Figure 2a).
These results were further validated by half endogenous
immunoprecipitation showing that Flag-PIAS3 co-immuno-
precipitated with endogenous NR4A1 and that endogenous
PIAS3 interacted with endogenous NR4A1 (Figures 2b
and c). Consistent with this, we found that the two proteins
co-localized in the nucleus (Supplementary Figure S1).
These data suggest that PIAS3 may function as a SUMO
E3 ligase for NR4A1.
SUMO modification of NR4A1 triggers polyubiquitination
and is stimulated by PIAS3 and reversed by SENP1.
Consistent with the notion that PIAS3 is a SUMO E3 ligase,
we observed that forced SUMO3 expression increased the
SUMO modification of NR4A1 (Figure 3a). Next, we
examined the interactions between NR4A1 ubiquitination
and SUMOylation. Increased SUMO3-modification of NR4A1
led to a concomitant increase in NR4A1 polyubiquitination
(Figure 3a). In addition, the PIAS3-induced poly-SUMO chain
conjugation to NR4A1 coincided with increased poly-ubiquitin
chain modification. The PIAS3-mediated induction of ubiqui-
tin/SUMO chain modification of NR4A1 led to a decrease in
Figure 1 NR4A1 undergoes SUMO2/3-mediated SUMOylation. (a) Immunoblot (IB) analysis of immunoprecipitated (IP) cell lysate from HEK293T cells that were transfected
with Flag-NR4A1 plus HA-SUMO1, -2 or -3 and either left untreated or treated for 5 h with 5 μM MG132. (b) Untreated or MG132-treated HeLa cells were collected, subjected to
IP using anti-NR4A1 antibody, and analyzed by SUMO2/3 IB
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the levels of non-SUMO- or ubiquitin-modified NR4A1
(Figure 3a).
SUMOylation is a reversible process, and SENPs have
been implicated as deconjugating enzymes in this process.
We investigated whether SUMO modification and SUMO
modification-triggered polyubiquitination of NR4A1 could be
reversed by SENPs. Wild-type SENP1 completely blocked
NR4A1-SUMO3 conjugation (Figure 3b). This effect was
critically dependent on SNEP1 protease activity, as shown
by the observation that the SENP1CSmutant, which lacks the
deconjugation enzymatic activity, did not have the same effect
as wild-type SENP1. In addition, SUMO conjugation-triggered
polyubiquitination of NR4A1 was clearly decreased by wild-
type SENP1 but not by the SENP1 CS mutant (Figure 3b).
Figure 2 NR4A1 interacts with the SUMO E3 ligase PIAS3. (a) HEK293T cells were transfected with Flag-NR4A1 and HA-PIAS as indicated. Cells were collected for
immunoprecipitation (IP) with Flag M2 beads and subjected to immunoblot (IB) analysis. (b) IP and IB analysis of HEK293T cells transfected with control vector or with
Flag-PIAS3. (c) HEK293T cells were collected for IP with NR4A1 antibody followed by PIAS3 IB analysis
Figure 3 The SUMO E3 ligase enhances NR4A1 SUMOylation, and the deSUMOylation enzyme decreases NR4A1 SUMOylation. (a and b) HEK293T cells stably
expressing Myc-Ub were transfected with Flag-NR4A1, HA-SUMO3, and PIAS3 (a) or with SENP WT/CS (b) as indicated. Cells were treated with the proteasome inhibitor
MG132 for (5 μM for 5 h) and then collected for immunoprecipitation (IP) and immunoblot (IB) analysis
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Taken together, these data indicate that SUMOmodification of
NR4A1 triggers its polyubiquitination and that this process is
reversible. Thus, the extent of NR4A1 SUMO modification
seems to be balanced by the activities of the SUMO-E3 ligase
PIAS3 and the SUMO deconjugating enzyme SENP1.
RNF4 mediates SUMO modification-triggered polyubiqui-
tination of NR4A1. We next tried to identify the E3 ubiquitin
ligase that mediated the SUMO-triggered polyubiquitination
of NR4A1. Several Ring finger proteins have been reported to
have a SIM,45,46 so we focused on these particular E3 ligases
as a possible candidate for interacting with SUMOylated
NR4A1. In the absence of the proteasome inhibitor MG132,
NR4A1 interacted weakly with the E3 ligase RNF4 CS mutant
(which lacks E3 ligase activity) but not with wild-type RNF4
(Figure 4a). SUMO chain-induced dimerization activates
RNF4 (ref. 47). Thus, RNF4 might interact transiently with
SUMOylated-NR4A1 and mediate its degradation. To test
this, we investigated the interaction between NR4A1 and
RNF4 in the presence of MG132. Ectopically expressed
NR4A1 bound endogenous RNF4, and this interaction was
strengthened by co-expression with SUMO2/3 or with the
SUMO-E3 ligase PIAS3 (Figure 4b), both of which stimulate
the SUMOylation of NR4A1. Importantly, the NR4A1-RNF4
interaction was disrupted in cells that were transfected with
wild-type SUMO-deconjugating enzyme SENP1 but not in
cells transfected with SENP1 CS (Figure 4b). Endogenous
interactions between NR4A1 and RNF4 could only be
detected in cells that were co-transfected with SUMO3 and
PIAS3 (Figure 4c). These results suggest that RNF4
recognizes SUMO-conjugated NR4A1.
We next performed an ubiquitination assay to verify the
involvement of RNF4 in the SUMO-triggered ubiquitination of
NR4A1. Ectopic expression of RNF4 promoted polyubiquiti-
nation of NR4A1, and this effect was clearer when exogenous
SUMO was co-expressed with RNF4 (Figure 4d). In the
absence of MG132 treatment, RNF4 depletion caused the
accumulation of NR4A1-SUMO conjugates that had higher
molecular weights (Figure 4e). Furthermore, RNF4 depletion
reduced basal and exogenous SUMO-triggered NR4A1
ubiquitination (Figure 4f). These results suggest that the
SUMOylation-triggered polyubiquitination of NR4A1 was
mitigated by RNF4 depletion. Taken together, these data
Figure 4 RNF4 is required for SUMOylation-triggered polyubiquitination of NR4A1. (a) HEK293T cells transfected with Flag-NR4A1 or V5-RNF4 WT/CS as indicated were
collected for immunoprecipitation (IP) and immunoblot (IB) analysis. (b) HEK293T cells were transfected with or without SENP1 WT/CS, PIAS3, or SUMO2/3 as indicated. Cells
were treated with the proteasome inhibitor MG132 (5 μM for 5 h) and then collected for IP and IB analysis. (c) Endogenous interactions between NR4A1 and RNF4 in
HEK293T cells transfected with SUMO3 and PIAS3. Cells were treated with MG132 (5 μM for 5 h) before harvesting. (d) HEK293T cells expressing Myc-Ub were transfected with
Flag-NR4A1, HA-SUMO2, or RNF4 as indicated. Cells were treated with MG132 (5 μM for 5 h) and collected for IP and IB analysis. (e) RNF4 depletion leads to the accumulation
of NR4A1 SUMO2/3 conjugates in the absence of MG132 treatment in HEK293T cells. shRNF4, small hairpin RNA-targeting RNF4. (f) HEK293T cells expressing Myc-Ub were
transfected with Flag-NR4A1 and HA-SUMO and infected with the RNF4 shRNA lentivirus. Cells were treated with MG132 (5 μM for 5 h) and collected for IP and IB analysis
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show that RNF4 mediates the polyubiquitination of
SUMO-modified NR4A1.
Stress-induced NR4A1 degrades quickly via
SUMOylation-triggered polyubiquitination and subse-
quent degradation. Having demonstrated that NR4A1
undergoes SUMOylation-triggered polyubiquitination, we
next wanted to determine the physiological significance of
this finding. Basal NR4A1 expression is low in vivo, but
expression is induced rapidly in different cell types and
organs by many types of stimuli, including serum, inflamma-
tory factors, growth factors, phorbol ester, and stress48. We
observed that NR4A1 expression in HeLa and HEK293T cells
is rapidly induced in response to 12-O-Tetradecanoylphorbol-
13-acetate (TPA) and is rapidly degraded afterwards. How-
ever, when cells were challenged with the proteasome
inhibitor MG132, the TPA-induced NR4A1 expression was
sustained (Figure 5a and data not shown). These results
confirm previous reports and suggest that stress-induced
NR4A1 proteins are rapidly targeted for degradation via the
proteasome. TPA treatment enhanced PIAS3-NR4A1 inter-
action and greatly increased SUMO modification and the
polyubiquitination of NR4A1 (Figure 5b and Supplementary
Figure S2). Thus, SUMOylation-triggered polyubiquitination
plays an important role in depleting stress-induced NR4A1
protein from cells.
To confirm this result, we expressed or knocked down the
expression of proteins that are responsible for SUMO
modification or SUMO modification-trigged polyubiquitination
in cells. TPA-induced NR4A1 degraded faster in SUMO2/3-
transfected cells than in control cells (Figure 5c). SUMO E3
ligase PIAS3 (PIAS3WT), but not ring domain-deleted mutant
of PIAS3 (PIAS3▲Ring), also accelerated NR4A1 degrada-
tion (Figure 5d). Consistent with these findings, ectopic
SENP1 (SENP1 WT) expression strongly and stably
increased both basal and TPA-induced NR4A1 expression,
Figure 5 NR4A1 expressed in response to TPA stimulation undergoes SUMOylation-mediated degradation. (a) HEK293T cells were treated with DMSO or the proteasome
inhibitor MG132 (5 μM for 5 h) along with TPA (100 ng/ml) for the indicated time. Cells were collected for immunoblot (IB) analysis. (b) HEK293T cells were treated with TPA
(100 ng/ml) and MG132 (5 μM) as indicated for 5 h. Cells were collected for immunoprecipitation (IP) with non-specific (ns) or anti-NR4A1 antibody followed by IB analysis.
(c) HEK293T cells were transfected with control vector, SUMO2, or SUMO3 plasmids as indicated. Cells were treated with TPA for the indicated time and collected for IB analysis.
(d) PIAS3WT but not the PIAS3▲Ring mutant accelerated the degradation of the induced NR4A1 in HEK293T cells. (e) IB analysis of cell lysate from HEK293T cells transfected
with control vector, SENP1 WT, or the SENP1 CS mutant and treated with TPA (100 ng/ml) for the indicated time. (f) RNF4 depletion using two independent shRNAs (#1 and #2)
increased and extended TPA-induced NR4A1 expression in Jurkat cells. shRNF4, small hairpin RNA-targeting RNF4. NS, non-specific. Actin was included as a loading control in
(a) and in (c–f)
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while the SENP CSmutant did not have this effect (Figure 5e).
RNF4 depletion by two independent shRNAs exhibited effects
similar to those of wild-type SENP1 (Figure 5f). Given a pivotal
role of the NR4A receptors in regulating immune cell
phenotype, we examined whether this new regulatory system
also occurs in human monocytes. As shown in THP-1 cells,
LPS stimulation rapidly induced NR4A1 expression and the
induced NR4A1 level was sustained by MG132 treatment
(Supplementary Figure S3a). Similarly, the LPS-induced
NR4A1 also degraded faster in cells expressing PIAS3 WT,
but not in cells expressing PIAS3▲Ring mutant
(Supplementary Figure S3b). Consistently, LPS-induced
NR4A1 was stabilized by ectopic expression of SENP1 WT
(but not the CSmutant) and depletion of either PIAS3 or RNF4
(Supplementary Figure S3c–e).
In line with this, PIAS3 inhibited and SENP1 enhanced the
transcriptional activity of NR4A1, while their mutants
PIAS3 ▲Ring and SENP1 CS lost these effects. RNF4
overexpression and knockdown repressed and upregulated
NR4A1 transcriptional activity, respectively (Supplementary
Figure S4). Taken together, our data demonstrate that the
degradation of stimuli-induced NR4A1 can be accelerated by
SUMO modification-triggered polyubiquitination and can be
inhibited by reversing this process.
Mutating two consensus SUMO modification sites stabi-
lizes NR4A1. In most cases, SUMO modification occurs
within a consensus modification site (ψKxD/E, where ψ
represents a bulky hydrophobic group). We analyzed the
protein sequence of NR4A1 and found two such consensus
sites (Figure 6a). Although single mutation of either site
(K101R or K577R) did not change the NR4A1 SUMO
modification or polyubiquitination, these modifications of
NR4A1 were absent when both sites were mutated (K101R
and K577R) (Figure 6b). Mutation of both sites in NR4A1 also
abrogated the interaction of NR4A1 with RNF4 (Figure 6c).
Thus, NR4A1 proteins that lack SUMO modification did not
associate with RNF4 and could not be targeted for
polyubiquitination by RNF4.
After mutating K to R at these two sites, the half-life of
NR4A1 was extended substantially (Figure 7a). In line with
this, mutant NR4A1 (K101/577R) had higher transcriptional
activity than wild-type NR4A1 (Figure 7b). NR4A1 negatively
regulates TNF-α- and IL-1β-induced NF-κB activation by
transcriptionally targeting IκBα expression.34 Compared to
wild-type NR4A1, the K101/577R mutant induced higher
expression of IκBα (Figure 7c) and exhibited more potent
repression of TNF-α- and IL-1β-induced NF-κB activity
(Figure 7d). NF-κB activation is involved in immune cell
survival.49,50 Consistent with this, the NR4A1 K101/577R
mutant more efficiently induced the levels of active caspase 3
in human mynocyte THP-1 cells (Supplementary Figure S5).
Annexin V/PI staining from flow cytometry (FACS) showed that
ectopic expression of NR4A1 WT in THP-1 cells
increased Annexin V positive cells and Annexin V/PI double
positive cells; this effect was more obviously observed when
THP-1 cells were ectopically expressed with NR4A1 K101-
/577R mutant (Figure 7e), suggesting that the SUMO
modification-deficient NR4A1 K101/577R mutant could more
potently induce apoptotic cell death in THP-1 cells. Taken
together, these data show that lysine 101 and lysine 577 are
the two major SUMO-conjugating sites in NR4A1; mutating
both of these two sites stabilizes NR4A1 and increases its
transcriptional regulation activity as well as its other biological
activities.
Discussion
In this study, we elucidated the mechanisms by which the
stability of the orphan nuclear receptor NR4A1 is regulated via
SUMOylation and subsequent ubiquitination. SUMOylation of
Figure 6 NR4A1 has two major SUMO modification sites. (a) Sequences and locations of putative NR4A1 SUMO modification sites in the human and mouse NR4A1 protein
sequences. (b) Double mutation of the NR4A1 SUMO modification sites (K101/577 R) blocked both NR4A1 SUMOylation and polyubiquitination in HEK293T cells. (c)
HEK293T cells expressing HA-SUMO3 were transfected with Flag-NR4A1 WT, single mutant (K101R or K577 R) and double mutant (K101/ 577R) as indicated and treated with
the proteasome inhibitor MG132 (5 μM for 5 h). Cells were then collected for immunoprecipitation (IP) and immunoblot (IB) analysis
SUMO-triggered ubiquitination-mediated degradation of NR4A1
F Zhou et al
1535
Cell Death and Differentiation
NR4A1 by the E3 SUMO ligase PIAS3 allows the
recruitment of the SUMO-interacting E3 ubiquitin ligase
RNF4, which triggers the polyubiquitination and subsequent
degradation of SUMOylated NR4A1. Thus, SENP1-mediated
SUMO-deconjugation of NR4A1 greatly antagonizes its
ubiquitination and subsequent proteosomal degradation.
Further, we demonstrated that a SUMO modification-
deficient NR4A1 mutant is more stable than the
wild-type protein and has a much more potent transcriptional
activity.
NR4A1 is an early response gene product; as such, the
basal levels of NR4A1 are low and NR4A1 is degraded rapidly
Figure 7 Mutation of two consensus SUMO modification sites stabilizes NR4A1 and increases its biological activities. (a) (Left panel) Immunoblot analysis shows that the
NR4A1 K101/577 R double mutant extends the half-life of NR4A1 in HeLa cells. (Right panel) The degradation rate of NR4A1 WTand the NR4A1 double mutant K101/577 R are
shown graphically after quantitative densitometry was performed. (b) Transcriptional activity analysis of wild-type (WT) NR4A1 and the double mutant K101/577 R using a NBRE-
Luc reporter in HEK293T cells. (c) Immunoblot analysis of HeLa cells infected with lentivirus expressing control vector, NR4A1 WT, or the NR4A1 K101/577 R mutant. (d) NF-κB
activity induced by TNF-α or IL-1β was inhibited more by the NR4A1 double mutant K101/577 R than by NR4A1 WT in HEK293T cells. (e) THP-1 cells infected with lentivirus
expressing a control vector, NR4A1 WTor the K101, 577 R double mutant were stained with Annexin V and Propidium Iodine (PI) and analyzed by FACS. (f) Working model of
SUMO modification-mediated NR4A1 ubiquitination and degradation
SUMO-triggered ubiquitination-mediated degradation of NR4A1
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after induction. This latter property is often observed for
early response gene products, as their activities are usually
required only transiently to trigger a particular process.20 This
is the first report of SUMOylation-triggered ubiquitination-
mediated degradation of an early response gene product. Our
findings, taken together with a recent proteomic study showing
that at least 10% of SUMOylated proteins are ubiquitinated,51
suggest that SUMOylation-mediated ubiquitination may occur
in other rapidly induced cellular responses.
NR4A1 stability and activity is known to be regulated by post-
translational modifications. Phosphorylation, which is mediated
by various extracellular cues and protein kinases, determines
the function of NR4A1 (refs 39–41). Acetylation and deacetyla-
tion induced by P300 and HDAC1 regulates NR4A1 protein
turnover.37 We now report another type of regulation that is
mediated by a different kind of reversible post-translational
modification. It is not known whether NR4A1 phosphorylation
modulates SUMOylation-triggered ubiquitination, and the
known phosphorylation sites are not in very close proximity to
the two SUMO attachment sites that we identified.
The two SUMOylation sites that we identified in NR4A1 are
highly conserved and can be found in zebrafish, frogs and
mammals. Inspection of the sequences of the NR4A1
paralogs, NR4A2 and NR4A3, reveals that these two isoforms
also have these two SUMOconjugation sites. The consecutive
SUMOylation and ubiquitination process is thus likely common
to other members of the NR4A1 family of proteins.
NR4A1 associates with RNF4 in a SUMOylation-dependent
manner, and SUMOylation-defective NR4A1 is more transcrip-
tionally active. RNF4 interacts with transcription (co)
factors.11,52–54 More recently, the interactome for RNF4 was
determined using a proteomic approach, and many transcrip-
tion factors were identified among its interaction partners.55
NR4A1 was not identified as an interaction partner, probably
because it was expressed at low levels in those experimental
conditions. Notably, RNF4 localizes to PML bodies.56 Interest-
ingly, NR4A1 localizes to the nucleus when expressed alone,
but when it is co-expressed with PML, both proteins co-localize
in a speckled pattern in the nucleus (Supplementary FigureS1).
Future studies should investigate whether SUMOylation-
triggered ubiquitination also plays a role in other NR4A1-
mediated effects downstream of other stimuli, such as
tumourigenesis, glucose and lipid homeostasis, and vascular
remodeling. Our results revealed the precise molecular
mechanisms that regulate reversible SUMO modification of
NR4A1 and control its stability. These mechanisms represent
potential targets for therapeutic intervention in diseases linked
to NR4A1 (dys) function.
Materials and Methods
Cell cultures. HEK293T and HeLa cells were cultured in Dulbecco’s modified
Eagle’s medium. Jurkat, RAW264.7 and THP-1 cells were cultured in RPMI 1640
medium supplemented with 10% FBS (Hyclone, Logan, Utah, USA) and 100 U/ml
penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA).
Plasmids and reagents. Flag-NR4A1 and Flag-NR4A1-2KR (K101/577R)
were amplified from pCMV-SPORT6 NR4A1 (Open Biosystems, Huntsville,
Alabama, USA) by PCR and inserted into the pLV-bc-CMV vector. The
HA-SUMO1-3 and the SENP1 WT and CS constructs were described
previously.57 HA-PIAS1, -3, Xα and Xβ were kindly provided by Dr. X.-H. Feng
(Baylor College of Medicine), and Flag-PIAS3 was provided by Dr. D. Baker (Leiden
University Medical Center). V5-RNF4 and RNF4 shRNAs58 were kindly provided by
Dr. A. shRNAs targeting human PIAS3 (#1, TRCN0000020784 and #2,
TRCN0000020786) were got from Sigma mission library. Vertegaal. 12-O-
tetradecanoylphorbol 13-acetate (TPA) and MG132 were purchased from Sigma
(MO, USA).
We used the following antibodies: β-actin (A5441, Sigma, St Louis, MO,USA), c-Myc
(a-14, sc-789, Santa Cruz Biotechnology, Santa Cruz, USA), HA (Y-11, sc-805, Santa Cruz
Biotechnology), HA (12CA5, produced in our laboratory), Flag (M2, Sigma), ubiquitin
(P4D1, Santa Cruz Biotechnology), V5 (Invitrogen). The anti-SUMO2/3 antibody was
provided by Dr. A. Vertegaal.
Lentiviral transduction. Lentivirus was produced by co-transfecting pLKO-1
(for the shRNA-knockdown) or pLV-bc-CMV (for cDNA expression) plasmids and the
helper plasmids pCMV-VSVG, pMDLg-RRE (gag/pol), and pRSV-REV into
HEK293T cells. Cell supernatants were collected 48 h after transfection and were
either used promptly to infect cells or were stored at − 80 °C.
To obtain stable cell lines, cells were infected at low confluence (20%) for 24 h with
lentiviral supernatant that was diluted 1:1 with normal culture medium in the presence
of 5 ng/ml polybrene (Sigma). Then, 48 h after infection, cells were placed under
puromycin selection for 1 week and passaged before use.
Immunoprecipitation and immunoblotting. As described
previously,59,60 cells were lysed by incubation with 1 ml of lysis buffer (20 mM
Tris-HCl, pH 7.4, 2 mM EDTA, 25 mM NaF, 1% Triton X-100) plus protease inhibitors
(Sigma) for 10 min at 4 °C. After centrifugation at 12 000 × g for 15 min, the lysates
were immunoprecipitated with antibodies and protein A-Sepharose (GE Healthcare
Bio-Sciences AB, Uppsala, Sweden) for 3 h at 4 °C. Subsequently, the precipitates
were washed three times with washing buffer (50 mM Tris-HCl, pH 8.0, 150 mM
NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% SDS), and the
immune complexes were eluted with sample buffer containing 1% SDS for 5 min at
95 °C and analyzed by SDS-PAGE.
Immunoblotting was performed as described previously61 using secondary
anti-mouse or anti-rabbit antibodies conjugated to horseradish peroxidase
(GE Healthcare, Buckinghamshire, UK) plus visualization with chemiluminescence.
SUMOylation and ubiquitination assays. For the in vivo SUMOylation
and ubiquitination assays, cells were washed with PBS (10 mM N-ethylmaleimide,
NEM) and lysed in two pellet volumes of RIPA buffer (20 mM NaP (pH 7.4), 150 mM
NaCl, 1% Triton, 0.5% sodium deoxycholate, and 1% SDS) supplemented with
protease inhibitors and 10 mM NEM. Lysates were boiled, diluted with RIPA buffer
containing 0.1% SDS, sonicated, and centrifuged at 4 °C (16,000 × g) for 15 min.
The supernatant was incubated with specific antibodies plus sepharose for 2 to 6 h
at 4 °C. After extensive washing, bound proteins were eluted with 2 × SDS sample
buffer and separated on SDS-PAGE followed by immunoblotting.
Transcriptional reporter assay. Cells were transfected and lysed as
described previously,62,63 and luciferase activities were measured using a
luminometer (Berthold Technologies, Bad Wildbad, Black Forest, Germany).
Reporter activity was normalized to β-Gal activity from a cotransfected internal
control plasmid. Experiments were performed in triplicate.
Statistical analysis. Statistical analyses were performed using a two-tailed
unpaired t-test. Po0.05 was considered significant.
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